Search clinical trials for: Pabociclib, Endocrine, Talazoparib,

Total 745 results

Samsung Medical Center

Not yet recruiting

PALbociclib Endocrine Therapy Followed by Talazo vs. Talazoz-Atezo Study (Young-PALETTA)

Premenopausal HR+/HER2- Metastatic Breast Cancer

Korea, Republic of
Swiss Group for Clinical Cancer Research
The Belgian Society of Medical Oncology

Terminated

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Breast Cancer

Switzerland, Belgium, Austria
Novartis Pharmaceuticals
Translational Research in Oncology

Active, not recruiting

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)

Early Breast Cancer

United States, Belgium, Canada, Italy, United Kingdom, Hungary, Taiwan, Australia, Germany, Spain, Austria, Russian Federation, Korea, Republic of, China, France, Brazil, Ireland, Argentina, Romania, Poland
Massachusetts General Hospital
Novartis

Recruiting

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER)

Breast Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment (RIBANNA)

Breast Cancer

Germany
Pfizer

Recruiting

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting. (PERFORM)

Breast Neoplasms

Austria, Germany
Novartis Pharmaceuticals

Recruiting

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia (PROSPERITY)

Breast Cancer

Russian Federation
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

Hormone Receptor Positive Advanced Breast Cancer

China
Novartis Pharmaceuticals

Completed

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)

Breast Cancer

United States
Novartis Pharmaceuticals

Withdrawn

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

Breast Cancer
ETOP IBCSG Partners Foundation
Pfizer

Recruiting

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

Breast Cancer Recurrent

Switzerland, Italy, France, Spain, Hungary, Austria
Pfizer

Recruiting

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Cancer

Japan
University of Milano Bicocca

Completed

Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer (ETIC)

DILI

Italy
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
Ottawa Hospital Research Institute

Recruiting

Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer

Breast Cancer

Canada
Alliance Foundation Trials, LLC.
Pfizer; Breast International Group; NSABP Foundation Inc; Austrian Breast & Colorectal... and other collaborators

Active, not recruiting

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

Breast Cancer

United States, Spain, Italy, Ireland, United Kingdom, Australia, Germany, Japan, Portugal, Taiwan, Canada, Israel, Netherlands, Switzerland, Belgium, Austria, Hungary, Korea, Republic of, Mexico, Poland, Sweden
Namik Kemal University

Not yet recruiting

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

Turkey
Ottawa Hospital Research Institute

Completed

Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance

Breast Cancer

Canada
American Society of Clinical Oncology
Patient-Centered Outcomes Research Institute

Not yet recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Metastatic Breast Cancer
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Peter MacCallum Cancer Centre, Australia

Terminated

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study (TAILOR)

Cancer

Australia
Institut Bergonié
Institut du Cancer de Montpellier - Val d'Aurelle; UNICANCER

Active, not recruiting

Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

Cancer

France
The Third Xiangya Hospital of Central South University

Not yet recruiting

TUPKRP Combined With MAB Therapy for LUTS/PCa

Quality of Life | Lower Urinary Tract Symptoms | Advanced Prostate Cancer | Overall Survival | Progression of Prostate Cancer
Kyoto Breast Cancer Research Network
Pfizer

Completed

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

Taiwan, Japan, Korea, Republic of, Australia, Hong Kong
MedSIR

Completed

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC (BioPER)

Metastatic Breast Cancer

Spain, Italy
Novartis Pharmaceuticals

Completed

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Metastatic Breast Cancer

United States
Seoul National University Hospital

Recruiting

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Advanced Breast Cancer

Korea, Republic of
University of Michigan Rogel Cancer Center

Withdrawn

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

CYP3A4*22
Second Affiliated Hospital, School of Medicine,...

Recruiting

Application of Radiomics in Breast Cancer

Breast Cancer | Elastography | Ultrasound | Radiomics | Pathology

China
ETOP IBCSG Partners Foundation
Alliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...

Active, not recruiting

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)

Early Breast Cancer

Korea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy

Prostate Cancer

Japan
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
Massachusetts General Hospital

Completed

Endocrinology Auto-Triggered e-Consults

Diabetes Mellitus

United States
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Institut Curie
Zionexa

Recruiting

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC)

Breast Carcinoma

France
Pfizer

Completed

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Neoplasms

China
Dana-Farber Cancer Institute

Not yet recruiting

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Breast Cancer | Breast Carcinoma | Breast Cancer Female

United States
University of Michigan Rogel Cancer Center
Johns Hopkins University; Memorial Sloan Kettering Cancer Center; University... and other collaborators

Active, not recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Breast Neoplasms

United States
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
George Washington University

Completed

Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study (THRIVE)

Overweight, Obesity and Other Hyperalimentation

United States
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer; National Institutes of Health (NIH); Allegheny Health Network

Active, not recruiting

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)

Breast Cancer

United States
Sudipto Mukherjee

Active, not recruiting

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United States, United Kingdom, Korea, Republic of, Australia, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

Fallopian Tube Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal Cancer AJCC v7 and other conditions

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine

Search clinical trials for: Pabociclib, Endocrine, Talazoparib,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations